Senolytics: Can Fisetin and Quercetin Clear Senescent Cells? A Practitioner's Evidence Review
Quick Answer
What are senolytics?
A practitioner's evidence review of natural senolytics — fisetin, quercetin, cyclical dosing protocols, the SASP mechanism, and an honest assessment of what the current science does and does not support.
What Are Senescent Cells and Why Do They Matter for Aging?
Cellular senescence is a state in which a cell permanently stops dividing but refuses to undergo apoptosis — the normal programmed cell death process. These cells are sometimes called "zombie cells" in the popular press because they persist in tissue long after their useful lifespan, metabolically active but no longer fulfilling their original function.
Cellular senescence is a cell state involved in various normal physiological processes and in age-related changes (Gorgoulis 2019). Senescent cells accumulate with age (Hickson 2019).
Senescent cells release inflammatory and tissue-remodeling factors, together called the senescence-associated secretory phenotype (SASP), which includes interleukin-6 and matrix metalloproteinases (Hickson 2019). In laboratory research, senescent cells have been linked to aging and age-related changes (Yousefzadeh 2018).
Emerging research suggests a possible role for removing senescent cells: in one study of aged mice, fisetin given late in life reduced age-related pathology and extended median and maximum lifespan (Yousefzadeh 2018). This is a single mouse study and has not been shown in humans; we believe this needs further study and verification.
Senolytics such as the combination of dasatinib and quercetin are described as acting by temporarily disabling the pro-survival networks that protect senescent cells (Hickson 2019). In one mouse and human tissue study, fisetin reduced senescence in only a subset of cell types (Yousefzadeh 2018).
Fisetin: The Most Potent Natural Senolytic?
Fisetin is a polyphenolic flavonol found naturally in strawberries, apples, grapes, onions, and cucumbers — though at concentrations far below what research suggests may be pharmacologically relevant for senolytic activity. Its emergence as a leading natural senolytic candidate traces directly to a landmark 2018 study published in EBioMedicine.
In a 2018 study, researchers screened 10 flavonoids in cultured senescent mouse and human fibroblasts, and fisetin was the most potent. In progeroid and aged mice, fisetin reduced senescence markers in several tissues, and in aged mice given fisetin late in life it extended median and maximum lifespan. Fisetin also reduced senescence in a subset of cells in human adipose tissue samples. This is a single preclinical study.
In a mouse study, treating progeroid and old mice with fisetin reduced senescence markers in multiple tissues, which the authors describe as consistent with a hit-and-run senolytic mechanism; fisetin also reduced senescence in a subset of cells in mouse and human fat-tissue samples (Yousefzadeh 2018). Human clinical evidence is still needed.
Human clinical evidence is still emerging. The Mayo Clinic is running AFFIRM-LITE (NCT03675724), a randomized, placebo-controlled phase 2 pilot of fisetin in adults aged 70 and older (planned enrollment 40). As of November 2026, the registry lists it as enrolling by invitation with no posted results. Until those data are reported, fisetin's senolytic activity in humans remains unestablished.
Dosing protocols for fisetin remain unsettled. In the 2018 mouse study, fisetin was given acutely or intermittently. No human dose of fisetin has been established.
FormulaForge does not make claims that fisetin supplementation clears senescent cells or treats any age-related condition. The research is promising but remains predominantly preclinical, and individuals considering fisetin should consult their healthcare provider.
Quercetin: The Established Senolytic Flavonoid
Quercetin is a widely studied flavonoid found in many plant foods. Its role as a senolytic was first described in the context of pharmaceutical combination therapy.
The original senolytic research from the Mayo Clinic identified quercetin as a potent senolytic when combined with dasatinib — a pharmaceutical tyrosine kinase inhibitor used in leukemia treatment. A first-in-human, open-label pilot study of the dasatinib-plus-quercetin (D+Q) combination in 14 adults with idiopathic pulmonary fibrosis reported it was feasible to give (all participants stayed in the study), with one serious adverse event; the authors called for larger randomized trials. The combination is thought to work synergistically because quercetin and dasatinib target overlapping but distinct pro-survival pathways in senescent cells.
The bioavailability challenge with quercetin is significant. Standard quercetin aglycone has low and highly variable oral bioavailability due to poor solubility and rapid first-pass metabolism. Quercefit — a proprietary quercetin phytosome formulation in which quercetin is complexed with food-grade lecithin — produced significantly higher peak plasma quercetin and overall exposure than unformulated quercetin in a single-dose randomized crossover pharmacokinetic study of 12 healthy volunteers authored by the manufacturer. It is a single small study.
Quercetin is frequently combined with fisetin in senolytic supplement stacks. The rationale for the combination mirrors the pharmaceutical Q+D approach: quercetin and fisetin may target partially overlapping survival pathways in senescent cells, potentially producing synergistic clearance that neither compound achieves as effectively alone. This combination has not been formally tested in human clinical trials, and the synergy hypothesis remains theoretical pending direct investigation.
No standard human dose of quercetin for senolytic purposes has been established. In two small published pilot studies, in people with lung or kidney disease, quercetin (1,000 to 1,250 mg per day) was given together with the prescription drug dasatinib under clinical supervision.
Cyclical vs Daily Dosing: The Protocol Debate
One of the most debated questions in practical senolytic supplementation is whether compounds like fisetin and quercetin should be taken daily or in periodic high-dose cycles — and if cycling, on what schedule.
In the fisetin mouse study, treatment was acute or intermittent rather than continuous, which the authors describe as consistent with a hit-and-run mechanism (Yousefzadeh 2018). The right schedule for people has not been established.
A critical limitation: no human randomized controlled trial has directly compared cyclical high-dose versus daily low-dose protocols for either fisetin or quercetin. The existing dosing recommendations are extrapolations from animal studies, pharmacokinetic modeling, and mechanistic reasoning — not direct clinical evidence. The field is in early days, and practitioners should communicate this uncertainty clearly to patients or clients considering senolytic supplementation.
Beyond Fisetin and Quercetin: The Senolytic Landscape
Fisetin and quercetin receive the most attention in the natural senolytic space, but they exist within a broader landscape of compounds — pharmaceutical, botanical, and otherwise — with varying degrees of senolytic or senomorphic (SASP-suppressing without cell clearance) activity.
Dasatinib plus quercetin has been studied in two small open-label human pilot studies (14 adults with idiopathic pulmonary fibrosis and 9 adults with diabetic kidney disease). Dasatinib is a prescription cancer drug, not a supplement.
Spermidine warrants distinction from senolytics proper. Spermidine is a polyamine found in wheat germ, fermented soy, and aged cheese that has gained significant attention for inducing autophagy — the cellular recycling process by which damaged organelles and misfolded proteins are cleared. Autophagy induction is mechanistically distinct from senolysis: autophagy supports cellular quality control within viable cells, while senolytics clear cells that have already entered an irreversible senescent state. Both processes are relevant to longevity biology, but they address different targets.
Hyperbaric oxygen therapy (HBOT) is worth noting as a non-supplement approach with published senescence-related evidence. A 2020 prospective trial in Aging (Albany NY) reported that 60 HBOT sessions in healthy adults aged 64 and older significantly reduced the percentage of senescent T helper and T cytotoxic cells in circulating blood and increased telomere length across several immune cell types — findings the authors interpreted as potential senolytic effects. This is mechanistically distinct from flavonoid-based senolytics, and the practical accessibility of HBOT limits its broad applicability, but it illustrates that the senolytic concept extends beyond oral supplementation.
What We Know and Don't Know: The Evidence Gap
The senolytic field is scientifically compelling and evolving rapidly — but it is important to be direct about the current state of human evidence and where the research frontier actually stands.
The majority of senolytic evidence remains preclinical. Most of the evidence that removing senescent cells extends lifespan or reduces age-related pathology comes from mouse studies using genetic and pharmacologic approaches. Whether similar effects occur in people taking oral supplements is unknown.
Human trials are early-stage and small in scale. The best human data are two small open-label pilot studies of dasatinib plus quercetin. In 14 adults with idiopathic pulmonary fibrosis, one serious adverse event was reported and respiratory symptoms, bruising and gastrointestinal discomfort were common; walking and chair-stand measures improved, while lung function and reported health did not change, and there was no control group. In 9 adults with diabetic kidney disease, there were fewer senescent cells in fat and skin samples and lower circulating SASP factors 11 days after a 3-day course. Neither study was randomized or placebo-controlled, and the fisetin trial listed above has no posted results.
The FDA does not approve dietary supplements for any use, and supplements may not be marketed to treat, cure or prevent disease. No supplement has been shown in humans to clear senescent cells.
There is a meaningful gap between consumer excitement and clinical validation. The longevity supplement market has moved faster than the science, and products are marketed with aspirational language that significantly overstates what the current evidence supports. Responsible supplementation means being transparent about the preclinical nature of most senolytic claims. For example, one small crossover study by the ingredient's manufacturer (12 healthy volunteers, single doses) found higher blood quercetin levels with a lecithin phytosome formulation (Quercefit) than with unformulated quercetin (Riva 2019).
Researchers use markers such as hs-CRP, IL-6 and p16INK4a expression, and some people use epigenetic age tests. None of these has been shown to confirm that a supplement affects senescent cells in an individual.
FormulaForge supports evidence-informed supplementation with transparency about uncertainty. We do not claim that any supplement reverses aging, treats disease, or clears senescent cells. The senolytics research is among the most exciting in longevity biology — and it deserves to be represented accurately, including its current limitations.
How we evaluate ingredient quality → Learn about our multi-factor scoring system and manufacturing standards.
Ready to formulate with Senolytics?
Build your personalized formula with research-backed dosing.
Start My FormulaFrequently Asked Questions
- What are senolytics?
- Senolytics are compounds — pharmaceutical or natural — that research suggests may selectively trigger apoptosis (programmed cell death) in senescent cells, sometimes called 'zombie cells,' while leaving healthy cells largely unaffected. Senescent cells accumulate with age and secrete inflammatory compounds (the SASP) that may contribute to tissue degradation. The senolytic hypothesis is that periodically reducing the burden of these cells could support healthspan. Most senolytic evidence is currently preclinical (animal models), with human trials still in early stages.
- Should I take fisetin or quercetin for senolytic support?
- The two compounds have different evidence profiles. In a 2018 study of 10 flavonoids in cultured cells and mice, fisetin was the most potent senolytic. In senolytic research, quercetin's human data come from two small pilot studies in which it was combined with the prescription drug dasatinib. Fisetin is the subject of the Mayo Clinic's AFFIRM-LITE pilot trial, which lists no posted results. For example, one small crossover study by the ingredient's manufacturer (12 healthy volunteers, single doses) found higher blood quercetin levels with a lecithin phytosome formulation (Quercefit) than with unformulated quercetin (Riva 2019). Neither compound has been proven to clear senescent cells in humans in a well-powered clinical trial — consult your healthcare provider before starting.
- What is the recommended dose of fisetin for senolytic use?
- There is no established human dose of fisetin for senolytic purposes. The mouse study used intermittent dosing.
- What is cyclical dosing for senolytics?
- Mouse studies used intermittent dosing; the right schedule for people is unknown. No human clinical trial has directly compared cyclical versus daily dosing, and the optimal cycle frequency has not been established in humans.
- Is fisetin and quercetin supplementation safe?
- The safety of fisetin and quercetin at the high doses used in senolytic research has not been established in humans. In a 14-person pilot of dasatinib plus quercetin, one serious adverse event and frequent mild-to-moderate events (respiratory symptoms, bruising, gastrointestinal discomfort) were reported. Talk with your healthcare provider before using these supplements, especially if you take prescription medicines. Quercetin may interact with certain medications including antibiotics (quinolones), blood thinners, and immunosuppressants. Fisetin's interaction profile is less well-characterized. Anyone taking prescription medications should consult their prescribing physician before using these supplements.
- How would I know if senolytic supplementation is working?
- There are no validated consumer-accessible biomarkers that directly measure senescent cell burden in tissues. Proxy measures used in research include inflammatory markers (hs-CRP, IL-6) measured via standard blood panels, epigenetic biological age tests (TruAge, GlycanAge), and p16INK4a expression in circulating T-cells (available through some research panels). Physical function measures — grip strength, gait speed, mobility — are used as functional endpoints in clinical trials. The honest answer is that current tools cannot definitively confirm senolytic activity from a supplement in an individual — response monitoring requires a longitudinal approach tracking multiple biomarkers over time.
- Can I combine fisetin and quercetin with other longevity supplements?
- Combinations of these compounds have not been tested together in human trials. Talk with your healthcare provider before combining supplements.
- Who should NOT take senolytic supplements?
- Individuals who should avoid fisetin or quercetin supplementation at senolytic doses without physician guidance include: those taking immunosuppressant medications (organ transplant recipients), those on anticoagulant or antiplatelet therapy, those taking certain antibiotics (quinolone class), pregnant or breastfeeding individuals, and those with known hypersensitivity to flavonoid compounds. People with autoimmune conditions should exercise particular caution, as the immunomodulatory effects of these compounds at high doses are not fully characterized. The 'senolytic dose' is substantially higher than typical supplement use and the safety data at these doses is limited compared to the extensive record at lower supplemental doses.
Related Pages
References
FormulaForge formulates and sells supplements containing the ingredients discussed on this page. Form Scores and ranks are built from bioavailability data and citations for each form, and whether we sell a form does not change either. How the Form Score works.